| P2093 | author name string | Darrell J Irvine | |
| | Tyson J Moyer | |
| | Andrew C Zmolek | |
| P2860 | cites work | Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction | Q84276325 |
| | The kinetics of soluble and particulate antigen trafficking in the afferent lymph, and its modulation by aluminum-based adjuvant | Q84634230 |
| | Delivery of polysaccharides using polymer particles: implications on size-dependent immunogenicity, opsonophagocytosis, and protective immunity | Q43700368 |
| | Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration | Q43888679 |
| | In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. | Q44490370 |
| | Secretion of adipokines by human adipose tissue in vivo: partitioning between capillary and lymphatic transport | Q44591257 |
| | Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system | Q45399710 |
| | Nanoparticles target distinct dendritic cell populations according to their size | Q45732404 |
| | Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. | Q46017170 |
| | Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial | Q46623264 |
| | Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose | Q47301856 |
| | Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors | Q47409832 |
| | The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles | Q48914128 |
| | Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. | Q50457532 |
| | Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. | Q50560920 |
| | Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. | Q50768287 |
| | A high-throughput nanoimmunoassay chip applied to large-scale vaccine adjuvant screening. | Q51533158 |
| | Liposome-encapsulated HIV-1 Gag p24 containing lipid A induces effector CD4+ T-cells, memory CD8+ T-cells, and pro-inflammatory cytokines. | Q51890485 |
| | CD8 T cell expansion and memory differentiation are facilitated by simultaneous and sustained exposure to antigenic and inflammatory milieu. | Q51968169 |
| | Molecular signature of CD8+ T cell exhaustion during chronic viral infection. | Q51970485 |
| | PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. | Q53076908 |
| | Activating B Cell Signaling with Defined Multivalent Ligands | Q56656698 |
| | Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function | Q56880717 |
| | Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response | Q57955486 |
| | Toll-dependent selection of microbial antigens for presentation by dendritic cells | Q59063722 |
| | Control of B-cell responses by Toll-like receptors | Q59066168 |
| | The Actin and Tetraspanin Networks Organize Receptor Nanoclusters to Regulate B Cell Receptor-Mediated Signaling | Q63409208 |
| | The influence of antigen organization on B cell responsiveness | Q72628042 |
| | Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation | Q78852123 |
| | B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node | Q80688189 |
| | Exploiting lymphatic transport and complement activation in nanoparticle vaccines | Q81305052 |
| | Innate immunity mediates follicular transport of particulate but not soluble protein antigen | Q83684751 |
| | Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age | Q24658073 |
| | Vaccine Adjuvants: from 1920 to 2015 and Beyond | Q26783879 |
| | Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice | Q28486624 |
| | Differential antigen processing by dendritic cell subsets in vivo | Q29615177 |
| | Programming the magnitude and persistence of antibody responses with innate immunity | Q30400144 |
| | Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies | Q30430925 |
| | Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection | Q30433900 |
| | Trans-nodal migration of resident dendritic cells into medullary interfollicular regions initiates immunity to influenza vaccine | Q30585157 |
| | A self-assembling peptide acting as an immune adjuvant | Q33640064 |
| | Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. | Q33760871 |
| | Structure-based programming of lymph-node targeting in molecular vaccines | Q33800766 |
| | Inflammatory cytokines as a third signal for T cell activation | Q33936084 |
| | Localization dose and time of antigens determine immune reactivity | Q33980378 |
| | Dissolving polymer microneedle patches for influenza vaccination | Q34049972 |
| | HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates | Q34085119 |
| | Dendritic cell subsets require cis-activation for cytotoxic CD8 T-cell induction | Q34127442 |
| | Antigen depot is not required for alum adjuvanticity | Q34235031 |
| | In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid | Q34413177 |
| | Monovalent ligation of the B cell receptor induces receptor activation but fails to promote antigen presentation. | Q34480372 |
| | Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development | Q34480617 |
| | Capturing complex 3D tissue physiology in vitro | Q34565076 |
| | GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives | Q34655188 |
| | Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses | Q34802680 |
| | Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. | Q34875973 |
| | Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance | Q34985424 |
| | Molecular determinants of immunogenicity: the immunon model of immune response | Q35031292 |
| | Duration of antigen availability influences the expansion and memory differentiation of T cells | Q35175877 |
| | Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling | Q35183935 |
| | Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. | Q37377550 |
| | A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. | Q37431320 |
| | Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination | Q37603557 |
| | Materials engineering for immunomodulation | Q37639157 |
| | Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques | Q37643792 |
| | Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants | Q37649282 |
| | Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns | Q37800358 |
| | The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant | Q37956385 |
| | Boosting antibody responses by targeting antigens to dendritic cells | Q37966312 |
| | Alum adjuvant: some of the tricks of the oldest adjuvant | Q37969028 |
| | The mechanism of action of MF59 - an innately attractive adjuvant formulation | Q38017390 |
| | Accelerating next-generation vaccine development for global disease prevention | Q38110775 |
| | Key roles of adjuvants in modern vaccines | Q38169040 |
| | Development and function of dendritic cell subsets | Q38212449 |
| | Implantable silk composite microneedles for programmable vaccine release kinetics and enhanced immunogenicity in transcutaneous immunization | Q38257857 |
| | The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles | Q38299407 |
| | Polymer multilayer tattooing for enhanced DNA vaccination | Q38499608 |
| | Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype | Q39180411 |
| | Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses | Q39398295 |
| | In situ regulation of DC subsets and T cells mediates tumor regression in mice | Q39885761 |
| | Infection-mimicking materials to program dendritic cells in situ | Q39896570 |
| | Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells | Q40068378 |
| | Covalently coupled immunostimulant heterodimers. | Q40459615 |
| | In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity | Q40937108 |
| | Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines | Q40998064 |
| | Composite dissolving microneedles for coordinated control of antigen and adjuvant delivery kinetics in transcutaneous vaccination | Q41213216 |
| | Conduits mediate transport of low-molecular-weight antigen to lymph node follicles | Q41291427 |
| | Vaccine adjuvant MF59 promotes retention of unprocessed antigen in lymph node macrophage compartments and follicular dendritic cells | Q41582364 |
| | A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human | Q41630579 |
| | Rational design of small molecules as vaccine adjuvants. | Q41655108 |
| | Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice | Q41695957 |
| | Dissolving microneedle delivery of nanoparticle-encapsulated antigen elicits efficient cross-priming and Th1 immune responses by murine Langerhans cells | Q41730559 |
| | A single-step immunization by sustained antigen release | Q41741707 |
| | Targeting and activation of antigen-specific B-cells by calcium phosphate nanoparticles loaded with protein antigen | Q42221772 |
| | Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response | Q42227086 |
| | Development and clinical study of a self-dissolving microneedle patch for transcutaneous immunization device | Q43630592 |
| | Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity | Q43638130 |
| | TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway | Q35220395 |
| | In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles | Q35229225 |
| | Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination | Q35518723 |
| | Contributions of humoral and cellular immunity to vaccine-induced protection in humans. | Q35615024 |
| | Persistent antigen presentation after acute vesicular stomatitis virus infection | Q35635383 |
| | Immunological mechanisms of vaccination | Q35659533 |
| | Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction | Q35709003 |
| | Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. | Q35836140 |
| | Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial | Q35925829 |
| | Antigen presentation kinetics control T cell/dendritic cell interactions and follicular helper T cell generation in vivo. | Q36022467 |
| | Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor | Q36082833 |
| | Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope | Q36083687 |
| | RETRACTED: Stabilization of vaccines and antibiotics in silk and eliminating the cold chain | Q36132649 |
| | Microneedles for drug and vaccine delivery | Q36164749 |
| | Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies | Q36167475 |
| | Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation | Q36228608 |
| | Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics | Q36236209 |
| | Triggering TLR signaling in vaccination | Q36323399 |
| | HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. | Q36345558 |
| | Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model | Q36383391 |
| | Antigen kinetics determines immune reactivity | Q36516144 |
| | Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients | Q36547213 |
| | Engineered lentivector targeting of dendritic cells for in vivo immunization | Q36629181 |
| | Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses | Q36693991 |
| | Designing tomorrow's vaccines | Q36730618 |
| | Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. | Q36766872 |
| | Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting | Q36939901 |
| | Nanoparticles and microparticles as vaccine-delivery systems | Q36968297 |
| | Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity | Q37103959 |
| | TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis | Q37120117 |
| | Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells | Q37139993 |
| | Toward an AIDS vaccine | Q37158259 |
| | A self-adjuvanting supramolecular vaccine carrying a folded protein antigen | Q37280623 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 799-808 | |
| P577 | publication date | 2016-03-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Beyond antigens and adjuvants: formulating future vaccines | |
| P478 | volume | 126 | |